Back to today’s briefing

Story perspectives

GSK to Acquire Nuvalent for $10.6 B, Gains Lung Cancer Pipeline

6/10/2026

41 8 Full Breakdown

Summary

Story summary

GSK will buy Boston-based Nuvalent for $10.6 billion, offering $124 per share—a 40% premium to the close.
The acquisition adds late-stage NSCLC drugs zidesamtinib and neladalkib, with FDA rulings due Sept. 18 and Nov. 27 2026, and Phase 1 HER2-NSCLC candidate NVL-330.
GSK will fund the deal with cash and debt, keep its credit rating unchanged, expects profitability from 2027, and its shares fell 3.6% while Nuvalent’s rose about 13% YTD.

History

Historical Context

In 1999 Pfizer launched a hostile bid for Warner-Lambert, completing a $111.8 billion acquisition that made it the world’s second-largest drugmaker. The wave of mega-mergers that followed—including Pfizer’s 2003 purchase of Pharmacia and GSK’s 2019 $10.6 billion Nuvalent buy—cemented consolidation as a defining trend in the pharmaceutical industry and prompting antitrust scrutiny.

1 of 2

Story summary

GSK will buy Boston-based Nuvalent for $10.6 billion, offering $124 per share—a 40% premium to the close.
The acquisition adds late-stage NSCLC drugs zidesamtinib and neladalkib, with FDA rulings due Sept. 18 and Nov. 27 2026, and Phase 1 HER2-NSCLC candidate NVL-330.
GSK will fund the deal with cash and debt, keep its credit rating unchanged, expects profitability from 2027, and its shares fell 3.6% while Nuvalent’s rose about 13% YTD.

1 / 2